Role of lentinan combined with AdIRF3 inhibiting breast cancer growth through enhancing IFN-β secretion / 中草药

ABSTRACT

Objective To investigate the effect of lentinan (LNT) combined with IRF3 expressing adenovirus vector on the anti-tumor therapy, and its underlying mechanism. Methods Balb/c bearing TUBO mice were treated with PBS, AdGFP, AdIRF3, LNT, and LNT combined with AdIRF3 to observe the tumor growth curve of mice. qPCR was used to detect the IFN-β level of tumor tissues. ELISPOT was to check the IFN-γ secretion of spleen cells. FACS was used to make sure the percentage of tumor infiltrated T cells. Balb/c-nu mice were inoculated with TUBO cells, and tumor growth was monitored. Anti-IFNAR1 antibody was injected to Babl/c bearing mice, and tumor growth was measured. Results Compared with control groups, LNT combined with AdIRF3 can inhibit the tumor growth and increase the IFN-γ secretion of TUBO-bearing mice. There was no significant difference of the percentage of tumor infiltrated Treg among groups, but the tumor infiltrated CD8+T was significantly higher in LNT combined with AdIRF3 treated mice group. There was no significant difference of tumor growth between Balb-nu mice inoculated with TUBO cells treated by LNT/AdIRF3 and PBS/AdGFP group. The tumor growth was not inhibited in Babl/c bearing mice injected with anti-IFNAR1 antibody and treated by LNT/AdIRF3. Conclusion LNT combined with AdIRF3 can inhibit the tumor growth by activating the IRF3-IFN signaling pathway.